Product Code: ETC095807 | Publication Date: Jul 2023 | Updated Date: Feb 2025 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
Indonesia is one of the rapidly growing markets for erythromycin. It has been estimated that the demand for erythromycin will witness a CAGR of 4% over the next five years in this country. The increase in demand is attributed to its availability and affordability, along with rising health awareness and increasing bacterial resistance to antibiotics. Moreover, this antibiotic is used as an anti-inflammatory agent in treating several chronic diseases such as pneumonia, sinusitis, bronchitis, rheumatic fever and skin infections. Additionally, it also assists in controlling acne breakouts caused by Propionibacterium acnes bacteria among adolescents.
The Indonesia market for erythromycin is witnessing an increase due to its safety profile compared to other antibiotics like penicillin derivatives or cephalosporins which are associated with adverse reactions at higher doses. Also, patients prefer oral dosage forms instead of intravenous injections because they are easier to administer and cause fewer side effects than injections do. Furthermore, government initiatives towards providing better healthcare facilities have added up to the need of erythromycin in Indonesia hospitals and clinics leading an upward trend being witnessed by this segment during recent times.
The major drivers behind the growth of Indonesia erythromycin market include increasing prevalence of bacterial infections due to poor hygiene levels coupled with high awareness about treatment options available among consumers from urban areas resulting into increased usage rate; widening patient base due to rise in geriatric population suffering from infectious/inflammatory conditions needing long term treatments; products approval & launches pushing sales volume upwards; presence & penetration of generic drugs supported by strong marketing campaigns; increased accessibility owing improved distribution channels throughout rural regions helping serve customers better; growing number pharmaceutical outlets & retail stores across cities enabling convenient purchase experiences etc., all collectively contributing towards positive projected on global level as well.
The COVID-19 pandemic has had a significant impact on the Indonesia Erythromycin market. The lockdown measures and travel restrictions imposed by the government in order to contain the spread of the virus have disrupted production, distribution, and sales activities across all sectors of the economy. This disruption has forced many pharmaceutical companies in Indonesia to reduce their production capacities either temporarily or permanently. Furthermore, due to decreased demand from hospitals for Erythromycin as well as other drugs, manufacturers are facing declining sales revenues while customers are experiencing uptake shortages.
One of the major challenges faced by producers of Erythromycin is that they need to maintain a consistent supply chain despite disruptions caused by COVID-19. Moreover, with increased competition from generic drug manufacturers and low pricing pressure among distributors/retailers further intensifying it becomes difficult for companies to sustain themselves financially during these uncertain times. Additionally, limited access to raw materials needed for producing this drug due to import bans put up by some countries is another challenge that needs urgent attention from Indonesia authorities if they wish to continue its manufacture within their borders.
Some key players operating in Indonesia Erythromycin market include Kalbe Farma Tbk., PT Darya Varia Laboratoria Tbk., Kimia Farma Tbk., Tempo Scan Pacific Tbk., Dexa Medica Group Companies etc. These companies are leveraging innovative strategies such as strategic collaborations with universities & research centers and intensive product promotional campaigns in order remain viable post pandemic times.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Indonesia Erythromycin Market Overview |
3.1 Indonesia Country Macro Economic Indicators |
3.2 Indonesia Erythromycin Market Revenues & Volume, 2021 & 2031F |
3.3 Indonesia Erythromycin Market - Industry Life Cycle |
3.4 Indonesia Erythromycin Market - Porter's Five Forces |
3.5 Indonesia Erythromycin Market Revenues & Volume Share, By Formulation, 2021 & 2031F |
3.6 Indonesia Erythromycin Market Revenues & Volume Share, By Therapeutic Indications, 2021 & 2031F |
3.7 Indonesia Erythromycin Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Indonesia Erythromycin Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Indonesia Erythromycin Market Trends |
6 Indonesia Erythromycin Market, By Types |
6.1 Indonesia Erythromycin Market, By Formulation |
6.1.1 Overview and Analysis |
6.1.2 Indonesia Erythromycin Market Revenues & Volume, By Formulation, 2018 - 2031F |
6.1.3 Indonesia Erythromycin Market Revenues & Volume, By Gel, 2018 - 2031F |
6.1.4 Indonesia Erythromycin Market Revenues & Volume, By Tablet, 2018 - 2031F |
6.1.5 Indonesia Erythromycin Market Revenues & Volume, By Topical Solution, 2018 - 2031F |
6.1.6 Indonesia Erythromycin Market Revenues & Volume, By Ointment, 2018 - 2031F |
6.1.7 Indonesia Erythromycin Market Revenues & Volume, By Others, 2018 - 2031F |
6.2 Indonesia Erythromycin Market, By Therapeutic Indications |
6.2.1 Overview and Analysis |
6.2.2 Indonesia Erythromycin Market Revenues & Volume, By Respiratory Tract Infections, 2018 - 2031F |
6.2.3 Indonesia Erythromycin Market Revenues & Volume, By Eye Infections, 2018 - 2031F |
6.2.4 Indonesia Erythromycin Market Revenues & Volume, By Ear Infections, 2018 - 2031F |
6.2.5 Indonesia Erythromycin Market Revenues & Volume, By Skin and Soft Tissue Infections, 2018 - 2031F |
6.2.6 Indonesia Erythromycin Market Revenues & Volume, By Gastro-intestinal Infections, 2018 - 2031F |
6.2.7 Indonesia Erythromycin Market Revenues & Volume, By Others, 2018 - 2031F |
6.3 Indonesia Erythromycin Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Indonesia Erythromycin Market Revenues & Volume, By Hospital Pharmacies, 2018 - 2031F |
6.3.3 Indonesia Erythromycin Market Revenues & Volume, By Retail Pharmacies, 2018 - 2031F |
6.3.4 Indonesia Erythromycin Market Revenues & Volume, By Online Pharmacies, 2018 - 2031F |
7 Indonesia Erythromycin Market Import-Export Trade Statistics |
7.1 Indonesia Erythromycin Market Export to Major Countries |
7.2 Indonesia Erythromycin Market Imports from Major Countries |
8 Indonesia Erythromycin Market Key Performance Indicators |
9 Indonesia Erythromycin Market - Opportunity Assessment |
9.1 Indonesia Erythromycin Market Opportunity Assessment, By Formulation, 2021 & 2031F |
9.2 Indonesia Erythromycin Market Opportunity Assessment, By Therapeutic Indications, 2021 & 2031F |
9.3 Indonesia Erythromycin Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Indonesia Erythromycin Market - Competitive Landscape |
10.1 Indonesia Erythromycin Market Revenue Share, By Companies, 2024 |
10.2 Indonesia Erythromycin Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |